<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id>
<journal-title-group>
<journal-title>Journal of Translational Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">1479-5876</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31578139</article-id>
<article-id pub-id-type="pmc">6775664</article-id>
<article-id pub-id-type="publisher-id">2076</article-id>
<article-id pub-id-type="doi">10.1186/s12967-019-2076-z</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Plasma peroxiredoxin changes and inflammatory cytokines support the involvement of neuro-inflammation and oxidative stress in Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Abruzzo</surname>
<given-names>P. M.</given-names>
</name>
<address>
<email>provvidenza.abruzzo2@unibo.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matté</surname>
<given-names>A.</given-names>
</name>
<address>
<email>alessandro.matte@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bolotta</surname>
<given-names>A.</given-names>
</name>
<address>
<email>alessandra.bolotta3@unibo.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Federti</surname>
<given-names>E.</given-names>
</name>
<address>
<email>enrica.federti@univr.it</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghezzo</surname>
<given-names>A.</given-names>
</name>
<address>
<email>alessandro.ghezzo2@unibo.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guarnieri</surname>
<given-names>T.</given-names>
</name>
<address>
<email>tiziana.guarnieri@unibo.it</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1932-7380</contrib-id>
<name>
<surname>Marini</surname>
<given-names>M.</given-names>
</name>
<address>
<email>marina.marini@unibo.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Posar</surname>
<given-names>A.</given-names>
</name>
<address>
<email>annio.posar@unibo.it</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Siciliano</surname>
<given-names>A.</given-names>
</name>
<address>
<email>angela.siciliano@univr.it</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>De Franceschi</surname>
<given-names>L.</given-names>
</name>
<address>
<email>lucia.defranceschi@univr.it</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Visconti</surname>
<given-names>P.</given-names>
</name>
<address>
<email>paola.visconti@ausl.bologna.it</email>
</address>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution>Department of Experimental, Diagnostic and Specialty Medicine, </institution><institution>University of Bologna School of Medicine, </institution></institution-wrap>Bologna, Italy </aff>
<aff id="Aff2"><label>2</label>IRCCS Fondazione Don Carlo Gnocchi, Via A. Capecelatro, 66, 20148 Milan, Italy </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1763 1124</institution-id><institution-id institution-id-type="GRID">grid.5611.3</institution-id><institution>Department of Medicine, </institution><institution>University of Verona Medical School, </institution></institution-wrap>Verona, Italy </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution>Department of Biological, Geological and Environmental Sciences, </institution><institution>University of Bologna, </institution></institution-wrap>Bologna, Italy </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution>Department of Biomedical and Neuromotor Sciences, </institution><institution>University of Bologna, </institution></institution-wrap>Via Ugo Foscolo 7, 40123 Bologna, Italy </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.492077.f</institution-id><institution>Child Neurology and Psychiatry Unit, </institution><institution>IRCCS Istituto delle Scienze Neurologiche di Bologna, </institution></institution-wrap>Via Altura, 3, 40139 Bologna, Italy </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>2</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>2</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>17</volume>
<elocation-id>332</elocation-id>
<history>
<date date-type="received">
<day>8</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">It has been established that children with Autism Spectrum Disorders (ASD) are affected by oxidative stress, the origin of which is still under investigation. In the present work, we evaluated inflammatory and pro-oxidant soluble signature in non-syndromic ASD and age-matched typically developing (TD) control children.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We analyzed leukocyte gene expression of inflammatory cytokines and inflammation/oxidative-stress related molecules in 21 ASD and 20 TD children. Moreover, in another—comparable—group of non-syndromic ASD (N = 22) and TD (N = 21) children, we analyzed for the first time the protein expression of the four members of the antioxidant enzyme family of peroxiredoxins (Prx) in both erythrocyte membranes and in plasma.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">The gene expression of IL6 and of HSP70i, a stress protein, was increased in ASD children. Moreover, gene expression of many inflammatory cytokines and inflammation/oxidative stress-related proteins correlated with clinical features, and appeared to be linked by a complex network of inter-correlations involving the Aryl Hydrocarbon Receptor signaling pathway. In addition, when the study of inter-correlations within the expression pattern of these molecules was extended to include the healthy subjects, the intrinsic physiological relationships of the inflammatory/oxidative stress network emerged. Plasma levels of Prx2 and Prx5 were remarkably increased in ASD compared to healthy controls, while no significant differences were found in red cell Prx levels.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">Previous findings reported elevated inflammatory cytokines in the plasma of ASD children, without clearly pointing to the presence of neuro-inflammation. On the other hand, the finding of microglia activation in autoptic specimens was clearly suggesting the presence of neuro-inflammation in ASD. Given the role of peroxiredoxins in the protection of brain cells against oxidative stress, the whole of our results, using peripheral data collected in living patients, support the involvement of neuro-inflammation in ASD, and generate a rational for neuro-inflammation as a possible therapeutic target and for plasma Prx5 as a novel indicator of ASD severity.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Autism Spectrum Disorder</kwd>
<kwd>Peroxiredoxins 1, 2, 3 and 5</kwd>
<kwd>Red cells</kwd>
<kwd>Oxidative stress</kwd>
<kwd>(Neuro)inflammation</kwd>
<kwd>Cytokines</kwd>
<kwd>AHR signaling pathway</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003407</institution-id>
<institution>Ministero dell’Istruzione, dell’Università e della Ricerca</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Fondi Ricerca Universitaria UNIVR (IT)</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>IRCCS Istituto delle Scienze Neurologiche di Bologna (IT)</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Legacy of the late Ms Marisa Cimadori</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par21">Autism Spectrum Disorder (ASD) is a heterogeneous group of pervasive neurodevelopmental disorders characterized by impairment in the areas of communication, social behavior, and restricted interests and activities [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>].</p>
<p id="Par22">ASD has a strong genetic basis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], with over 100 identified monogenic syndromes [<xref ref-type="bibr" rid="CR6">6</xref>], a high number of susceptibility genes, of copy number variation (CNV) loci, and of rare genetic mutations/variants; however, genetics alone accounts to only 30–35% of ASD cases [<xref ref-type="bibr" rid="CR7">7</xref>]. Indeed, despite the high concordance among homozygous twins, a “broader autism phenotype” can be recognizable, though in a milder form, in the majority of siblings and parents of ASD subjects [<xref ref-type="bibr" rid="CR8">8</xref>], thus suggesting the presence of still unidentified molecular defects and the interplay with environmental factors. In fact, environmental factors, as diverse as exposure to toxicants, composition of the enteric microbiota, and immune dysregulation [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>], have been suggested to play a role in the establishment of the autistic phenotype, thus accounting for the remaining 65–70% of ASD cases. By affecting epigenetic modifications altering gene expression levels [<xref ref-type="bibr" rid="CR12">12</xref>], they are supposed to interact with a still ill-defined “susceptible” genome.</p>
<p id="Par23">Thus, non-syndromic ASD appears as a complex genetic trait, resulting from the combination of multiple de novo mutations, CNV, rare genetic variants and epigenetic regulation, with possible additive effects. Such etiological complexity forms the basis of the heterogeneity of the disease and challenges the attempts of finding therapeutic solutions.</p>
<p id="Par24">Since social communication, skills and range of interests and activities are the most affected areas in ASD subjects, researchers primarily focus on the identification of mutations impairing the correct neuronal functioning of central nervous system (CNS). As a matter of fact, a significant number of potential ASD candidate genes is involved in processes of cell-to-cell communication between neurons or between neural and microglial cells. However, being oxidative stress and inflammation present in ASD children, the possible contribution of neuroinflammation in the pathogenesis of ASD has recently gained growing attention [<xref ref-type="bibr" rid="CR13">13</xref>]. This has been also invocated in a number of psychiatric disorders, such as major depressive disorder, bipolar disorder, and schizophrenia, even though the exact underlying mechanisms are still lacking [<xref ref-type="bibr" rid="CR14">14</xref>]. The analysis of post-mortem brain from ASD subjects suggests that microglia activation or dysfunction may be itself caused by an increased inflammatory response and oxidation [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. These findings, together with the recent evidence of an increase in soluble pro-inflammatory cytokines in blood and cerebrospinal fluid in ASD patients, support the involvement of neuroinflammation in the pathogenesis of ASD [<xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. Indeed, children with ASD bear hallmarks of abnormalities in systemic redox balance [<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR24">24</xref>] as well as of increase in soluble makers of inflammation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Using red cells as cell model to explore oxidative stress in ASD, we reported abnormal red cell membrane lipid composition, reflecting increased pro-oxidant environment in ASD subjects [<xref ref-type="bibr" rid="CR23">23</xref>], and, more recently, the presence of advanced glycation end-products in plasma and urine of ASD children and the up-regulation of pro-inflammatory and anti-oxidant systems in isolated polymorphonuclear cells [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
<p id="Par25">Peroxiredoxins (Prxs) are ubiquitous anti-oxidants with a multifunction profile, acting as peroxidase scavengers but also as atypical molecular chaperones [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR35">35</xref>]. Prxs might be also released by different cell types in response to inflammatory stimuli or oxidation, contributing to the modulation of the cytokine storm [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Neurons express Prx2 and 5, similarly to other cells such as erythrocytes, adipocytes or cardiomyocytes [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. In a mouse model of brain ischemia, Prx2 and/or Prx5 have been also detected outside brain cells, contributing to the modulation of microglia and to the local modulation of inflammatory response [<xref ref-type="bibr" rid="CR34">34</xref>]. In addition, treatment with Anti-Prx5 antibody after the ischemic events beneficially affects the infarct size and the mouse neurologic outcomes [<xref ref-type="bibr" rid="CR34">34</xref>]. These findings are in agreement with previous studies in both cell-based and animal-based systems, showing the importance of Prxs in neuronal homeostasis and in cell defense against oxidation [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Noteworthy, increased expression of Prx5 has been reported in psychiatric disorders such as schizophrenia or bipolar disorder [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], whereas Prx2 has been found to be up-regulated in frontal cortex of subjects with neurodegenerative disorders including Down syndrome [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
<p id="Par26">Here, we compared red cell membrane and plasma levels of Prx in ASD and typically developing (TD) children and show that plasma Prx2 and Prx5 correlate with ASD. Moreover, we analyzed the gene expression network of inflammatory cytokines and inflammation/oxidative stress-related proteins and its relation with clinical features, which led us to suggest the protective role played by plasma Prxs and the involvement of the Aryl Hydrocarbon Receptor signaling pathway in ASD children.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Ethics statement</title>
<p id="Par27">The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures were approved by Local Ethical Committee (Azienda USL Bologna, CE 10020-n.30, 06/04/2010 prot. 45424/10-03 and CE 13062, 23/12/2013; prot. N.1198/CE). Written consent was obtained from all parents and, whenever possible, also from children through pictures and simplified information.</p>
</sec>
<sec id="Sec4">
<title>Subjects</title>
<p id="Par28">Two highly comparable groups of children were studied. The first group was the source of leukocytes for RNA extraction and evaluation of the gene expression. It was composed of 21 children diagnosed with non-syndromic ASD children [17 males and 4 females, aged (mean ± SD) 6.8 years] and 20 TD children [14 males and 6 females, aged (mean ± SD) 7.6 years]. Demographic parameters and clinical features of this group have been published by Ghezzo et al. [<xref ref-type="bibr" rid="CR23">23</xref>]. The second group was made up of 22 non-syndromic ASD children (17 males and 5 females), aged (mean ± SD) 7.84 ± 1.86 years and 21 TD children [14 males and 7 females, aged (mean ± SD) 9.47 ± 2 years]. Demographic parameters and clinical features of this group have been published by Bolotta et al. [<xref ref-type="bibr" rid="CR28">28</xref>]. Blood samples from this group were the source of erythrocytes and plasma for the evaluation of Prx levels. Within each group, both the non-parametric comparison of the average age of ASD and TD and the comparison by gender (Chi-square test) were not significant, confirming the comparability between cases and controls. All children were recruited by the Child Neuropsychiatry Unit of the Bellaria Hospital (IRCCS, Bologna) within the local community. The patients underwent a clinical diagnostic assessment and a comprehensive neurological work up, including electroencephalography (recorded both awake and sleeping), cerebral magnetic resonance imaging, CGH Array and molecular assay for Fragile X and MECP2. Childhood Autism Rating Scale (CARS) total scores ranged from mild to severe autistic features; developmental scores varied from normal IQ to severe cognitive impairment. Control TD children were recruited in the same local community and were free of cognitive, learning and psychiatric problems. All subjects did not take any dietary supplement in the 4 months preceding the biochemical and clinical evaluations and were free of any inflammatory or infective problems.</p>
</sec>
<sec id="Sec5">
<title>Blood samples and their handling</title>
<p id="Par29">Blood samples were collected in Na<sub>2</sub>-EDTA vacutainers. Basal hematological parameters were examined by routine laboratory techniques. Plasma was obtained by centrifugation. Peripheral blood mononuclear cells (PBMC) were separated by a discontinuous Ficoll density gradient.</p>
</sec>
<sec id="Sec6">
<title>RNA extraction, cDNA synthesis and RT-PCR analysis</title>
<p id="Par30">PBMCs were lysed in 1 mL Trizol<sup>®</sup> Reagent (Invitrogen, Italy) and RNA was extracted, quality controlled and reverse transcribed as previously described in detail [<xref ref-type="bibr" rid="CR47">47</xref>]. Quantitative Real-Time PCR (qRT-PCR) was performed by a CFX96 real-time thermal cycler using the SsoAdvanced™ Universal SYBR<sup>®</sup> Green Supermix (Biorad, USA). All primers used in this study (Table <xref ref-type="table" rid="Tab1">1</xref>) were custom designed with the help of the Primer Blast, Primer3 and AMPLIFY free software; whenever possible, primers were designed so as to span an exon–exon junction. Primers were obtained from GENOSYS (Sigma, USA). For normalization purposes, the expression of the housekeeping genes Actin-beta and GAPDH was quantified. Data were analyzed by using the CFX Manager and the qBase software and expressed as means ± confidence interval.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Primer sequences and amplicon length of the genes studied by qRT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Unigene accession no.</th><th align="left">Gene ID</th><th align="left">Gene</th><th align="left">Left primer</th><th align="left">Right primer</th><th align="left">Amplicon length (bp)</th></tr></thead><tbody><tr><td align="left">Hs.171189</td><td align="char" char=".">196</td><td align="left">AHR</td><td align="left">CTTCCAAGCGGCATAGAGAC</td><td align="left">AGTTATCCTGGCCTCCGTTT</td><td align="char" char=".">198</td></tr><tr><td align="left">Hs.274402</td><td align="char" char=".">3303</td><td align="left">HSPA1A<sup>a,b</sup></td><td align="left">CCCTGATCAAGCGCAACT</td><td align="left">CTCGTACACCTGGATCAGCA</td><td align="char" char=".">98</td></tr><tr><td align="left">Hs.654458</td><td align="char" char=".">3569</td><td align="left">IL6</td><td align="left">CAATGAGGAGACTTGCCTGGT</td><td align="left">AGCTGCGCAGAATGAGATGA</td><td align="char" char=".">275</td></tr><tr><td align="left">Hs.193717</td><td align="char" char=".">3586</td><td align="left">IL10</td><td align="left">GGCGCTGTCATCGATTTCTTC</td><td align="left">GCCACCCTGATGTCTCAGTT</td><td align="char" char=".">181</td></tr><tr><td align="left">Hs.126256</td><td align="char" char=".">3553</td><td align="left">IL1 beta</td><td align="left">AGCCATGGCAGAAGTACCTG</td><td align="left">CCTGGAAGGAGCACTTCATCT</td><td align="char" char=".">116</td></tr><tr><td align="left">Hs.673</td><td align="char" char=".">3592</td><td align="left">IL12A</td><td align="left">GCTCCAGAAGGCCAGACAAA</td><td align="left">GCCAGGCAACTCCCATTAGT</td><td align="char" char=".">183</td></tr><tr><td align="left">Hs.201978</td><td align="char" char=".">5742</td><td align="left">PTGS1<sup>b</sup></td><td align="left">AGCTCGTAGGAGAGAAGGAGAT</td><td align="left">AGTGTGGCCGTCTTGACAAT</td><td align="char" char=".">253</td></tr><tr><td align="left">Hs.196384</td><td align="char" char=".">5743</td><td align="left">PTGS2<sup>b</sup></td><td align="left">CAAATTGCTGGCAGGGTTGC</td><td align="left">AGGGCTTCAGCATAAAGCGT</td><td align="char" char=".">139</td></tr><tr><td align="left">Hs.432121</td><td align="char" char=".">7001</td><td align="left">PRDX2</td><td align="left">ACGAGCATGGGGAAGTTTGT</td><td align="left">GCCTTTCCTGGGTCAGCATA</td><td align="char" char=".">201</td></tr><tr><td align="left">Hs.502823</td><td align="char" char=".">25824</td><td align="left">PRDX5</td><td align="left">TCTTTGGGAATCGACGTCTC</td><td align="left">ATTGCAGAAATCTGGCCAAC</td><td align="char" char=".">229</td></tr><tr><td align="left">Hs.463059</td><td align="char" char=".">6774</td><td align="left">STAT3</td><td align="left">CGGAGAAGCATCGTGAGTGA</td><td align="left">CTCTTCCAGTCAGCCAGCTC</td><td align="char" char=".">95</td></tr><tr><td align="left">Hs.241570</td><td align="char" char=".">7124</td><td align="left">TNF-alpha</td><td align="left">CCCCAGGGACCTCTCTCTAA</td><td align="left">TCTCAGCTCCACGCCATT</td><td align="char" char=".">172</td></tr><tr><td align="left">Hs.520640</td><td align="char" char=".">60</td><td align="left">Actin-beta<sup>c</sup></td><td align="left">TGTGGCATCCACGAAACTAC</td><td align="left">TGATCTTGATCTTCATTGTGCT</td><td align="char" char=".">175</td></tr><tr><td align="left">Hs.544577</td><td align="char" char=".">2597</td><td align="left">GAPDH<sup>c</sup></td><td align="left">GGCCTCCAAGGAGTAAGACC</td><td align="left">CTGTGAGGAGGGGAGATTCA</td><td align="char" char=".">130</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>These primers recognize also HSPA1B, a minor isoform of HSPA1A</p><p><sup>b</sup>HSPA1A, protein name HSP70, inducible form; PTGS1 and PTGS2, protein name COX1 and COX2 (CICLOOXYGENASE 1 AND 2)</p><p><sup>c</sup>Actin-beta and GADPH were the housekeeping genes utilized in the gene expression study</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec7">
<title>Red cell membrane ghost preparation</title>
<p id="Par31">Blood was centrifuged at 3000<italic>g</italic> for 5 min at 4 °C to remove plasma, passed through cotton to remove white cells, and washed three times with choline wash solution (CWS: 175 mM choline, 1 mM MgCl<sub>2</sub>, 10 mM Tris-MOPS pH 7.4 at 4 °C, 320–340 mOsm) [<xref ref-type="bibr" rid="CR48">48</xref>]. Packed red cells were lysed in phosphate lysis buffer (PLB: 5 mM Na<sub>2</sub>HPO<sub>4</sub> pH 8.0, added of a protease inhibitor cocktail tablet, 3 mM benzamidine, 1 mM Na<sub>3</sub>VO<sub>4</sub> final concentration) and washed in PLB 5 times to obtain almost white ghosts. Whenever Prx2 was evaluated in SDS-PAGE analysis, 100 mM of NEM was added to the PLB to avoid possible artifacts due to Prx2 oxidation after cell lysis [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR49">49</xref>].</p>
</sec>
<sec id="Sec8">
<title>Immunoblot analysis of red cell membrane and plasma</title>
<p id="Par32">Mono-dimensional electrophoresis was carried out as previously described [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Gels were transferred to nitrocellulose membranes for immuno-blot analysis with specific antibodies: anti-peroxiredoxin-1 (Prx1, polyclonal Ab, Abcam, UK), anti-peroxiredoxin-2 (Prx2, clone 1E8, Abcam, UK), anti-peroxiredoxin-3 (Prx3, polyclonal Ab, Abcam, UK) and anti-peroxiredoxin-5 (Prx5, clone 3F11, Abcam, UK); Actin (anti-actin; Sigma Aldrich, USA) and anti-IgG were used as loading controls. Secondary anti-rabbit IgG and anti-mouse IgG HRP conjugated were from GE Healthcare. Blots were developed using the chemiluminescence reagent Luminata HRP Chemiluminescence detection reagents. Densytometric analysis of band intensities was carried out using Quantity One analysis software (Bio-Rad, USA).</p>
</sec>
<sec id="Sec9">
<title>Statistics</title>
<p id="Par33">Normality tests were applied to all numeric variables, following which appropriate parametric tests (ANOVA, Student’s t for independent data) or the nonparametric equivalent (Wilcoxon-Mann–Whitney) were used to compare ASD and TD data. RT-PCR data are expressed as means ± confidence interval, where a significance level of 0.05 corresponds to the 95% confidence level. Non-parametric correlation (Spearman’s rho) was used to correlate clinical features and biochemical data in the ASD group (non-parametric ANOVA for cognitive/developmental level). Differences were considered significant at p &lt; 0.05. To account for multiple testing we used the Benjamini and Hochberg false discovery rate (FDR). FDR corrected p-values (pFDR) were evaluated separately for (a) correlations between gene expression of cytokines and inflammation/oxidation-related molecules and clinical features; (b) inter-correlations between gene expression of cytokines and inflammation/oxidation-related genes; (c) correlations of peroxiredoxins (proteins) with clinical features and (d) inter-correlations of peroxiredoxins (proteins).</p>
</sec>
</sec>
<sec id="Sec10">
<title>Results</title>
<sec id="Sec11">
<title>Pro-inflammatory signature characterizes peripheral blood mononuclear cells from ASD patients</title>
<p id="Par34">Gene expression of cytokines and inflammation/oxidation-related molecules was examined in PBMC from the first group of ASD and TD children. For each gene studied, Table <xref ref-type="table" rid="Tab2">2</xref> reports ASD/TD ratio (± confidence interval), as well as the result of correlation tests with clinical features.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cytokines and inflammation/oxidation-related genes in leukocytes of ASD and TD children</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Inflammation/oxidation-related genes</th><th align="left">Fold change (ratio ASD/TD)</th><th align="left">95% confidence interval (CI)</th><th align="left">Two-sided <italic>p</italic> value for ASD vs TD difference</th><th align="left">Correlation with total CARS score</th><th align="left">Correlation with hyperactivity</th><th align="left">Correlation with stereotypies</th><th align="left">Correlation with cognitive level</th></tr></thead><tbody><tr><td align="left">AHR</td><td align="char" char=".">0.77</td><td align="left">0.471–1.281</td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0025</underline>
</p><p>
<underline>r = 0.70</underline>
</p><p>
<underline>pFDR = 0.12</underline>
</p></td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">HSP70i</td><td align="char" char=".">1.787</td><td align="left">1.227–2.602</td><td align="left">
<underline>p &lt; 0.01</underline>
</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">IL6</td><td align="char" char=".">2.204</td><td align="left">1.246–3.898</td><td align="left">
<underline>p &lt; 0.01</underline>
</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">IL10</td><td align="char" char=".">1.187</td><td align="left">0.690–2.043</td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0246</underline>
</p><p>
<underline>r = 0.55</underline>
</p><p>
<underline>pFDR = 0.17</underline>
</p></td><td align="left"><p>
<underline>p = 0.0128</underline>
</p><p>
<underline>r = 0.6</underline>
</p><p>
<underline>pFDR =0.12</underline>
</p></td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0377</underline>
</p><p>
<underline>r = 0.49</underline>
</p><p>
<underline>pFDR = 0.23</underline>
</p></td></tr><tr><td align="left">IL12A</td><td align="char" char=".">1.537</td><td align="left">0.893–2.646</td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0043</underline>
</p><p>
<underline>r = 0.67</underline>
</p><p>
<underline>pFDR = 0.13</underline>
</p></td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0197</underline>
</p><p>
<underline>r = 0.58</underline>
</p><p>
<underline>pFDR = 0.16</underline>
</p></td><td align="left">NS</td></tr><tr><td align="left">IL1 beta</td><td align="char" char=".">1.339</td><td align="left">0.779–2.303</td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.007</underline>
</p><p>
<underline>r = 0.64</underline>
</p><p>
<underline>pFDR = 0.11</underline>
</p></td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">COX1</td><td align="char" char=".">1.025</td><td align="left">0.785–1.337</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">COX2</td><td align="char" char=".">1.312</td><td align="left">0.788–2.184</td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0435</underline>
</p><p>
<underline>r = 0.51</underline>
</p><p>
<underline>pFDR = 0.21</underline>
</p></td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">PRX2</td><td align="char" char=".">1.038</td><td align="left">0.867–1.243</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left"><p>
<underline>p = 0.0111</underline>
</p><p>
<underline>r = 0.62</underline>
</p><p>
<underline>pFDR = 0.13</underline>
</p></td><td align="left">NS</td></tr><tr><td align="left">PRX5</td><td align="char" char=".">0.983</td><td align="left">0.884–1.092</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">STAT3</td><td align="char" char=".">0.952</td><td align="left">0.382–2.376</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left">TNF-alpha</td><td align="char" char=".">0.999</td><td align="left">0.567–1.759</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr></tbody></table><table-wrap-foot><p>Statistically significant correlations are underlined</p><p><italic>ASD</italic> Autism Spectrum Disorders, <italic>TD</italic> typically developing, <italic>CARS</italic> Childhood Autism Rating Scale, <italic>AHR</italic> Aryl Hydrocarbon Receptor, <italic>HSP70i</italic> Heat Shock Protein 70, inducible form, <italic>IL</italic> interleukin, <italic>COX</italic> cyclooxygenase, <italic>PRX</italic> peroxiredoxin, <italic>STAT3</italic> Signal Transducer and Activator of Transcription 3, <italic>TNF-alpha</italic> Tumor Necrosis Factor-alpha, <italic>NS</italic> not significant, <italic>r</italic> correlation coefficient</p></table-wrap-foot></table-wrap>
</p>
<p id="Par35">Comparisons between the ASD and the TD group of children revealed significant differences in the leukocyte expression of IL6, a major inflammatory cytokine, and of HSP70i, perhaps the most important chaperon involved in cellular defense mechanisms. Moreover, the gene expression of some inflammation/oxidation related genes (namely AHR, IL10, IL12A, IL1 beta, COX2 and PRX2) positively correlated with some ASD clinical features, although, after applying the False Discovery Rate test, correlations lost statistical significance. Remarkably, the gene expression of some cytokines and inflammation-related proteins was inter-correlated, thus suggesting a possible functional crosstalk within this pro-inflammatory network (Table <xref ref-type="table" rid="Tab3">3</xref>). Again, the application of the False Discovery Rate test caused some of the inter-correlations to lose statistical significance. Of note, PRX5 expression inversely correlated with that of AHR, of COX2 and STAT3. These findings support a pro-inflammatory environment characterizing ASD patients and requiring efficient cytoprotective systems such as peroxiredoxins. The existence of inter-correlations within the gene expression of cytokines and inflammation-related products was put into test in the whole set of studied subjects belonging to the first group, i.e. both ASD and TD children. Half the inter-correlations within the gene expression of some cytokines and inflammation-related products were a general feature, not restricted to ASD patients. PRX5 expression inversely correlated with that of COX2 and STAT3 also in the general population, thus enforcing the concept of its role in inflammatory contexts.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Correlations between gene expression of cytokines and inflammation/oxidation-related molecules</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cytokine or inflammation-related molecules</th><th align="left">AHR</th><th align="left">HSP70i</th><th align="left">IL6</th><th align="left">IL10</th><th align="left">IL12A</th><th align="left">IL1 beta</th><th align="left">COX1</th><th align="left">COX2</th><th align="left">PRX2</th><th align="left">PRX5</th><th align="left">STAT3</th><th align="left">TNF-alpha</th></tr></thead><tbody><tr><td align="left">AHR</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0014</underline>
</p><p>
<underline>r = 0.75</underline>
</p><p>
<underline>pFDR = 0.031</underline>
</p></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0265</underline>
</p><p>
<underline>r = 0.56</underline>
</p><p>
<underline>pFDR = 0.159</underline>
</p></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0458</underline>
</p><p>
<underline>r = 0.51</underline>
</p><p>
<underline>pFDR = 0.178</underline>
</p></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0281</underline>
</p><p>
<underline>r = − 0.55</underline>
</p><p>
<underline>pFDR = 0.154</underline>
</p></td><td align="left"><p>
<underline>p = 0.0027</underline>
</p><p>
<underline>r = 0.70</underline>
</p><p>
<underline>pFDR = 0.036</underline>
</p></td><td align="left"><p>
<underline>p = 0.0417</underline>
</p><p>
<underline>r = 0.51</underline>
</p><p>
<underline>pFDR = 0.183</underline>
</p></td></tr><tr><td align="left">HSP70i</td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0176</underline>
</p><p>
<underline>r = − 0.58</underline>
</p><p>
<underline>pFDR = 0.129</underline>
</p></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0161</underline>
</p><p>
<underline>r = − 0.59</underline>
</p><p>
<underline>pFDR = 0.132</underline>
</p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">IL6</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0079</underline>
</p><p>
<underline>r = 0.64</underline>
</p><p>
<underline>pFDR = 0.075</underline>
</p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">IL10</td><td align="left"><p><italic>p</italic> = <italic>0.0112</italic></p><p><italic>r</italic> = <italic>0.44</italic></p><p><italic>pFDR</italic> = <italic>0.082</italic></p></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0484</italic></p><p><italic>r</italic> = <italic>0.35</italic></p><p><italic>pFDR</italic> = <italic>0.213</italic></p></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0012</underline>
</p><p>
<underline>r = 0.73</underline>
</p><p>
<underline>pFDR = 0.040</underline>
</p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0010</underline>
</p><p>
<underline>r = 0.74</underline>
</p><p>
<underline>pFDR = 0.066</underline>
</p></td></tr><tr><td align="left">IL12A</td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0346</italic></p><p><italic>r</italic> = − <italic>0,37</italic></p><p><italic>pFDR</italic> = <italic>0.19</italic></p></td><td align="left"><p><italic>p</italic> &lt; <italic>0.0001</italic></p><p><italic>r</italic> = <italic>0.63</italic></p><p><italic>pFDR</italic> = <italic>0.003</italic></p></td><td align="left"><p><italic>p</italic> = <italic>0.0049</italic></p><p><italic>r</italic> = <italic>0.48</italic></p><p><italic>pFDR</italic> = <italic>0.064</italic></p></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0059</underline>
</p><p>
<underline>r = 0.65</underline>
</p><p>
<underline>pFDR = 0.065</underline>
</p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">IL1 beta</td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.006</italic></p><p><italic>r</italic> = − <italic>0.47</italic></p><p><italic>pFDR</italic> = <italic>0.057</italic></p></td><td align="left"><p><italic>p</italic> = <italic>0.0053</italic></p><p><italic>r</italic> = <italic>0.47</italic></p><p><italic>pFDR</italic> = <italic>0.058</italic></p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0015</underline>
</p><p>
<underline>r = 0.73</underline>
</p><p>
<underline>pFDR = 0.025</underline>
</p></td></tr><tr><td align="left">COX1</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0420</underline>
</p><p>
<underline>r = 0.65</underline>
</p><p>
<underline>pFDR = 0.173</underline>
</p></td><td align="left"></td></tr><tr><td align="left">COX2</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0320</underline>
</p><p>
<underline>r = − 0.69</underline>
</p><p>
<underline>pFDR = 0.162</underline>
</p></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">PRX2</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">PRX5</td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0368</italic></p><p><italic>r</italic> = − <italic>0.36</italic></p><p><italic>pFDR</italic> = <italic>0.187</italic></p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0014</italic></p><p><italic>r</italic> = − <italic>0.53</italic></p><p><italic>pFDR</italic> = <italic>0.023</italic></p></td><td align="left"></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0386</underline>
</p><p>
<underline>r = − 0.52</underline>
</p><p>
<underline>pFDR = 0.182</underline>
</p></td><td align="left"></td></tr><tr><td align="left">STAT3</td><td align="left"><p><italic>p</italic> &lt; <italic>0.0001</italic></p><p><italic>r</italic> = <italic>0.69</italic></p><p><italic>pFDR</italic> = <italic>0.007</italic></p></td><td align="left"></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0176</italic></p><p><italic>r</italic> = <italic>0.41</italic></p><p><italic>pFDR</italic> = <italic>0.116</italic></p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0484</italic></p><p><italic>r</italic> = <italic>0.35</italic></p><p><italic>pFDR</italic> = <italic>0.213</italic></p></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0221</italic></p><p><italic>r</italic> = − <italic>0.40</italic></p><p><italic>pFDR</italic> = <italic>0.133</italic></p></td><td align="left"></td><td align="left"><p>
<underline>p = 0.0196</underline>
</p><p>
<underline>r = 0.58</underline>
</p><p>
<underline>pFDR = 0.129</underline>
</p></td></tr><tr><td align="left">TNF-alpha</td><td align="left"><p><italic>p</italic> = <italic>0.0194</italic></p><p><italic>r</italic> = <italic>0.40</italic></p><p><italic>pFDR</italic> = <italic>0.128</italic></p></td><td align="left"><p><italic>p</italic> = <italic>0.0435</italic></p><p><italic>r</italic> = − <italic>0.35</italic></p><p><italic>pFDR</italic> = <italic>0.205</italic></p></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0002</italic></p><p><italic>r</italic> = <italic>0.60</italic></p><p><italic>pFDR</italic> = <italic>0.004</italic></p></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"><p><italic>p</italic> = <italic>0.0092</italic></p><p><italic>r</italic> = <italic>0.45</italic></p><p><italic>pFDR</italic> = <italic>0.076</italic></p></td><td align="left"></td></tr></tbody></table><table-wrap-foot><p>Significant correlations (p ≤ 0.05) are shown. Correlations found in ASD children alone are shown in underline; correlations found in the whole population (ASD and TD children) are shown in italic</p></table-wrap-foot></table-wrap>
</p>
<sec id="Sec12">
<title>Prx2 and Prx5 significantly increase in plasma from ASD patients</title>
<p id="Par36">In the present study, we used red cells to evaluate Prx2 and Prx5 membrane association as a marker of membrane oxidation in ASD patients [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR33">33</xref>]. Prx2 and Prx5 are differently expressed in red cells, the former being more abundant than the latter [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. As shown in Fig. <xref ref-type="fig" rid="Fig1">1</xref>a, no significant differences in Prx2 red cell membrane association in ASD patients was found in comparison with normal controls. Similar results were also obtained when Prx5 membrane translocation was studied in red cells from both groups of subjects (data not shown).<fig id="Fig1"><label>Fig. 1</label><caption><p>Upper panels. Immunoblot analysis with specific antibodies against <bold>a</bold> peroxiredoxin-2 (Prx2) in red cell membrane; <bold>b</bold> peroxiredoxin-2 (Prx2) in plasma; <bold>c</bold> peroxiredoxin-5 (Prx5) in plasma. Healthy controls (TD) and subjects with Autism Spectrum Disorder (ASD) were compared. Actin was used as loading control protein. One representative gel from three sets of separate experiments with similar results is presented. Lower panels. Densitometric analysis of immunoblots as in upper panels are shown as dot-plots</p></caption><graphic id="MO1" xlink:href="12967_2019_2076_Fig1_HTML"></graphic></fig></p>
<p id="Par37">Since Prxs are released by different cell types in response to inflammation and might contribute to the release of pro-inflammatory cytokines [<xref ref-type="bibr" rid="CR54">54</xref>], we evaluated Prx2 and Prx5 plasma levels in ASD and healthy controls. As shown in Fig. <xref ref-type="fig" rid="Fig1">1</xref>b, plasma Prx2 was significantly higher in ASD patients with respect to control subjects. In addition, plasma Prx5 was markedly increased in ASD patients when compared to healthy subjects. No major change in plasma Prx1 and Prx3 levels were observed in ASD patients compared to healthy controls (data not shown).</p>
<p id="Par38">We then evaluated the relation between Prx2 red cell membrane translocation or Prx5 plasma levels and ASD clinical presentation. Table <xref ref-type="table" rid="Tab4">4</xref> shows that the amount of Prx2 associated to the red cell membrane, though not significantly increased in ASD compared to TD subjects, was nevertheless negatively correlated with some ASD clinical features; the same was true for the amount of Prx5 in the plasma. This underscores the protective role of Prxs, since it suggests that the ability of transferring Prx2 to the erythrocyte cell membrane and of releasing Prx5 in the plasma goes in hand with a milder ASD phenotype.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Correlations of peroxiredoxins (protein amount) and clinical features</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"></th><th align="left">Age (months)</th><th align="left">Onset pattern: 1 (early); 2 (regressive); 3 (mixed)</th><th align="left">Brief non verbal IQ*</th><th align="left">ADOS score**</th><th align="left">CARS total score</th><th align="left">CARS Activity Level item score</th><th align="left">CARS body use (sterotypes) item score</th><th align="left">CARS verbal communication item score</th><th align="left">Non verbal communication Item score</th><th align="left">CARS total number of items whose score was ≥ 3</th><th align="left">Prx2/IgG in plasma</th><th align="left">Prx5/IgG in plasma</th></tr></thead><tbody><tr><td align="left">Prx2/actin in RBC</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left"><p>p = 0.027</p><p>r = − 0.47</p><p>pFDR = 0.13</p></td><td align="left"><p>p = 0.0043</p><p>r = − 0.58</p><p>pFDR = 0.13</p></td><td align="left">NS</td><td align="left">NS</td><td align="left"><p>p = 0.020</p><p>r = − 0.49</p><p>pFDR = 0.12</p></td><td align="left"><p>p = 0.01</p><p>r = − 0.5</p><p>pFDR = 0.15</p></td><td align="left">NS</td><td align="left"><p>p = 0.0048</p><p>r = 0.59</p><p>pFDR = 0.01</p></td></tr><tr><td align="left">Prx2/IgG in plasma</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left"></td><td align="left">NS</td></tr><tr><td align="left">Prx5/IgG in plasma</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left"><p>p = 0.021</p><p>r = − 0.5</p><p>pFDR = 0.16</p></td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left"><p>p = 0.022</p><p>r = − 0.5</p><p>pFDR = 0.13</p></td><td align="left"></td><td align="left"></td></tr></tbody></table><table-wrap-foot><p><italic>RBC</italic> red blood cell, <italic>Prx</italic> peroxiredoxin, <italic>IgG</italic> immunoglobulin G, <italic>ADOS</italic> Autism Diagnostic Observation Schedule, <italic>CARS</italic> Childhood Autism Rating Scale</p><p>*Cognitive level: ≥ 70, normal; 50-69, mild cognitive impairment; 35-49, moderate cognitive impairment; &lt; 35, severe cognitive impairment [<xref ref-type="bibr" rid="CR55">55</xref>]</p><p>**ADOS modules 1 or 2 (Total score Autism cut off = 12)</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec13">
<title>Plasma Prx5 levels are suggestive of ASD</title>
<p id="Par39">Since the difference in Prx5 plasma levels between ASD and TD subjects was highly significant (p &lt; 0.0001 by Mann–Whitney test), we calculated the Receiver Operating Characteristic (ROC) curve. The Area Under the Curve (AUC) value for plasma Prx5 resulted 0.938 (Fig. <xref ref-type="fig" rid="Fig2">2</xref>), thus suggesting that plasma Prx5 levels could be used to support ASD diagnosis with satisfactory indices of specificity and sensitivity.<fig id="Fig2"><label>Fig. 2</label><caption><p>Receiver Operating Characteristic (ROC) curve showing that plasma Prx5 levels are able to identify ASD from TD subjects with high sensitivity and high specificity. The closer Area Under the Curve (AUC) is to 1.0, the higher are the sensitivity and the specificity of the comparison</p></caption><graphic id="MO2" xlink:href="12967_2019_2076_Fig2_HTML"></graphic></fig>
</p>
</sec>
</sec>
</sec>
<sec id="Sec14">
<title>Discussion</title>
<p id="Par40">Here, we show a pro-inflammatory signature in PBMCs from ASD patients and report for the first time the increase in plasma Prx5 levels. Although the source of Prx5 in the peripheral circulation is largely unknown, by reporting that Prx5 is involved not only in the local modulation of the inflammatory response but specifically in neuroprotection mechanisms [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR56">56</xref>–<xref ref-type="bibr" rid="CR59">59</xref>], literature data are suggestive of the involvement of neuroinflammatory processes in ASD patients.</p>
<p id="Par41">The main evidence of the involvement of CNS inflammation in ASD comes from autoptic studies carried out on ASD subjects, reporting microglial and astrocytic activation, in different brain areas [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Remarkably, CNS inflammation might also account for the GABAergic/glutamatergic imbalance and the consequential glutamate excitotoxicity described in a group of ASD children [<xref ref-type="bibr" rid="CR62">62</xref>]. Moreover, the fact that seizures associate with high frequency to autism made Theoharides and Zhang [<xref ref-type="bibr" rid="CR63">63</xref>] suggest the association of ASD with neuroinflammation.</p>
<p id="Par42">The second line of evidence is based on increase in plasma level cytokines, chemokines and prostaglandins in ASD children when compared with age-matched TD children [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. In a subgroup of ASD children, independently of the gravity of clinical symptoms, we found increased expression of IL6. Noteworthy, IL6 is viewed to play a crucial role in the development and plasticity of CNS [<xref ref-type="bibr" rid="CR68">68</xref>] and it has been described to be involved in maternal immune activation (MIA), which may contribute to the development of autism, again through the establishment of prenatal pro-inflammatory pathways (reviewed in [<xref ref-type="bibr" rid="CR69">69</xref>]). IL6 has been linked to the pathogenesis of autism since it is involved in the homeostasis between neuro- and gliogenesis [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] and is synergistically induced by xenobiotics [<xref ref-type="bibr" rid="CR72">72</xref>], the kynurenine pathway [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>] and by the Aryl Hydrocarbon Receptor (AHR) [<xref ref-type="bibr" rid="CR75">75</xref>].</p>
<p id="Par43">In our study, we found that the gene expression of a number of cytokines and inflammation/oxidation-related molecules, though not significantly increased in ASD, was inter-correlated and correlated also with ASD severity. This observation led us to postulate the involvement of the AHR signaling pathway in ASD. By interacting with the xenobiotic response element (XRE), AHR is one of the major regulators of phase I target genes. AHR gene expression directly correlated with IL10, IL1 beta, COX2, STAT3 and TNF-alpha expression in the ASD leukocyte samples. Worth noting, the above-mentioned IL6 inducers may directly stimulate AHR [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]; in turn, AHR signaling may also mediate anti-inflammatory responses through IL10 induction [<xref ref-type="bibr" rid="CR78">78</xref>]. Table <xref ref-type="table" rid="Tab3">3</xref> also shows that some correlations between cytokine gene expression were independent from the subject’s disease status, thus underscoring the physiological inter-relationships of the inflammation-related pathways. For instance, AHR and STAT3 expression displayed a strong inter-correlation (p &lt; 0.0001, pFDR 0.007) when all subjects (both TD and ASD children) were considered; this is in agreement with what reported by Stobbe-Maicherski et al. [<xref ref-type="bibr" rid="CR79">79</xref>], who demonstrated that STAT3 binds to a STAT motif in AHR promoter, thus modulating AHR expression. Of note, AHR is a cellular biosensor, which is activated by a great variety of environmental molecules. As its activation can evoke an inflammatory outcome, its involvement in ASD could suggest the hypothesis of an environmental contribution in the pathogenesis of ASD. The intermediate products of phase I enzymes are postulated to serve as potential inducers of NRF2 pathway/phase II enzymes, which provide protection against oxidative stress. Notably, NRF2 gene expression was found to be increased in PBMC from ASD subjects [<xref ref-type="bibr" rid="CR28">28</xref>]. This is of interest for ASD since the NRF2 pathway plays an important role in neuroprotection mechanisms [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
<p id="Par44">An additional layer of complexity comes from the recent understanding of the role of AHR in the regulation of intestinal immunity [<xref ref-type="bibr" rid="CR81">81</xref>]. The central and enteric nervous systems are integrated in what is dubbed the “brain-gut axis”, a bidirectional communication system which makes use of the neural, endocrine, immune, and metabolic pathways, and includes the role of the gut flora as a source of a wide range of neuroactive molecules, regulating a host of CNS activities, affecting health, well-being, behavior, immunity. The concept that altered communication between the gut microbiome and the brain may play an important role in human brain disorders has recently received considerable attention [<xref ref-type="bibr" rid="CR82">82</xref>]; in particular it has been suggested to be a possible causative mechanism contributing to ASD pathogenesis [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Notably, the increase in ASD children of inflammation markers, which may result by the additive effects of central brain neuroinflammation and specific alterations of the intestinal mucosa, has been recently described [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Of note, the expression of the cytoprotective and anti-oxidant molecules HSP70i and PRX5 was <italic>negatively</italic> correlated with that of inflammatory cytokines such as IL6, IL12A, IL1 beta and COX2.</p>
<p id="Par45">The novel observation reporting the increase in plasma Prx5 as characterizing signature in ASD patients might well be the third evidence of the occurrence of neuroinflammation in ASD, given the Prx involvement in neuronal homeostatic responses [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Prx5 might act as anti-oxidant, atypical molecular chaperone inside the cells and as modulator of local inflammatory response outside the cells [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Over-expression of Prxs has been reported in subjects with Down syndrome and in patients with neurodegenerative disorders such as Alzheimer or Parkinson disease, suggesting a neuroprotective role of Prxs in these disorders [<xref ref-type="bibr" rid="CR44">44</xref>]. Noteworthy, increased plasma levels of Prx1 and 3 have been described in 20 patients with autism [<xref ref-type="bibr" rid="CR88">88</xref>]. In our cohort, we did not find significant differences in plasma level for Prx1 and Prx3. This might be related either to the number of patients studied or to the methodologic approach. Rather, we report here a significant increase in plasma Prx2 and Prx5 levels in ASD children. Among Prxs, Prx5 has been shown to be specifically increased in brain from Alzheimer’s disease patients and to be released outside brain cells in response to local neuroinflammation during post-ischemic events [<xref ref-type="bibr" rid="CR38">38</xref>]. The importance of Prx5 against neurotoxic damage is also supported by evidence of reduced severity of stroke-related neurologic damage in Prx5 treated mice [<xref ref-type="bibr" rid="CR38">38</xref>]. Worth noting, according to our study, the area under the ROC curve indicates that Prx5 may be used as a biomarker for ASD. However, the comparison was made here with TD children, whereas bona-fide biomarkers should be able to aid in differential diagnosis with other neurodevelopmental disorders: to this purpose, further studies should be performed.</p>
</sec>
<sec id="Sec15">
<title>Conclusions</title>
<p id="Par46">Although the present study has some limitation such as its explorative profile and the small number of ASD patients studied, the plasma level of Prx5 emerges as a new and direct suggestion—obtained in living patients—of the involvement of neuroinflammation in the pathogenesis of ASD, which adds to evidences coming from autoptic data and from the evaluation of inflammation markers. It may be interesting to note that peripheral markers may, in this context, be used to track central nervous system abnormalities. Finally, these findings lend to the view that neuro-inflammation may become a possible therapeutic target in ASD children. Future studies should be designed to evaluate the clinical relevance of plasma Prx5 in a larger cohort of ASD subjects.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>ADOS</term>
<def>
<p id="Par5">Autism Diagnostic Observation Schedule</p>
</def>
</def-item>
<def-item>
<term>AHR</term>
<def>
<p id="Par6">Aryl Hydrocarbon Receptor</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p id="Par7">Autism Spectrum Disorder</p>
</def>
</def-item>
<def-item>
<term>CARS</term>
<def>
<p id="Par8">Childhood Autism Rating Scale</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p id="Par9">central nervous system</p>
</def>
</def-item>
<def-item>
<term>COX</term>
<def>
<p id="Par10">cyclooxygenase</p>
</def>
</def-item>
<def-item>
<term>HS70i</term>
<def>
<p id="Par11">Heat Shock Protein 70, inducible form</p>
</def>
</def-item>
<def-item>
<term>IgG</term>
<def>
<p id="Par12">immunoglobulin G</p>
</def>
</def-item>
<def-item>
<term>IL</term>
<def>
<p id="Par13">interleukine</p>
</def>
</def-item>
<def-item>
<term>PBMC</term>
<def>
<p id="Par14">peripheral blood mononuclear cells</p>
</def>
</def-item>
<def-item>
<term>MIA</term>
<def>
<p id="Par15">maternal immune activation</p>
</def>
</def-item>
<def-item>
<term>PRX</term>
<def>
<p id="Par16">peroxiredoxin</p>
</def>
</def-item>
<def-item>
<term>RBC</term>
<def>
<p id="Par17">red blood cells</p>
</def>
</def-item>
<def-item>
<term>STAT</term>
<def>
<p id="Par18">Signal Transducers and Activators of Transcription (i.e. transcription factors)</p>
</def>
</def-item>
<def-item>
<term>TD</term>
<def>
<p id="Par19">typically developing</p>
</def>
</def-item>
<def-item>
<term>TNF</term>
<def>
<p id="Par20">tumor necrosis factor</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher's Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>A. Bolotta—Shares first name</p>
</fn>
<fn>
<p>L. De Franceschi—Shares co-seniorship</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>The Authors are grateful to the children who contributed a blood sample and to their families.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>PMA, AG, MM and LDF designed the research; PV and AP enrolled the autistic and control subjects, carried out the clinical and neurological evaluation and supervised blood withdrawal; AB organized the handling of biological samples and kept the records; PMA, AB, AM, EF, AS performed the experimental procedures; all Authors were involved in the analysis of data and in drafting the manuscript. All authors edited the final manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This work received funding from the Ministry of Research and University and a legacy of late Ms Maria Luisa Cimadori, a member of ANGSA (Associazione Nazionale Genitori Soggetti Autistici) to MM; LDF was funded by Fondi Ricerca Universitaria (FUR)_UNIVR; PV was funded by IRCCS Istituto delle Scienze Neurologiche di Bologna. The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>The Authors declare that all original data are available for inspection and evaluation.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par47">The present study complies with the guidelines laid down in the Declaration of Helsinki; all procedures involving human patients were approved by Local Ethical Committee: for group 1, Azienda USL Bologna, CE 10020- n.30, 06/04/2010 Prot. N. 45424/10-03; for group 2, Azienda USL Bologna, Imola, Ferrara, CE 13062, 23/12/2013; Prot. N. 1198/CE). Written consent was obtained from parents as well as from children through pictures and simplified information.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par48">The Authors, and the Institutions they belong to, consent to the publication of their research. Written consent to publish individual children’s details (Table <xref ref-type="table" rid="Tab2">2</xref>) was given by their parents or legal guardians.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par49">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and statistical manual of mental disorders
          <year>2013</year>
<edition>5</edition>
<publisher-loc>Washington DC</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Genetics of Autism Spectrum Disorders</article-title>
<source/>Trends Cognit Sci
          <year>2011</year>
<volume>15</volume>
<fpage>409</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="doi">10.1016/j.tics.2011.07.003</pub-id>
<pub-id pub-id-type="pmid">21855394</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeron</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The genetics and neurobiology of ESSENCE: the third Birgit Olsson lecture</article-title>
<source/>Nord J Psychiatry
          <year>2016</year>
<volume>70</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.3109/08039488.2015.1042519</pub-id>
<pub-id pub-id-type="pmid">25971862</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lichtenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kuja-Halkola</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Reichenberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The heritability of Autism Spectrum Disorder</article-title>
<source/>JAMA
          <year>2017</year>
<volume>318</volume>
<fpage>1182</fpage>
<lpage>1184</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2017</pub-id>
<pub-id pub-id-type="pmid">28973605</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Brouwer</surname>
<given-names>CR</given-names>
</name>
</person-group>
<article-title>Systematic reconstruction of autism biology from massive genetic mutation profiles</article-title>
<source/>Sci Adv.
          <year>2018</year>
<volume>4</volume>
<fpage>e1701799</fpage>
<pub-id pub-id-type="doi">10.1126/sciadv.1701799</pub-id>
<pub-id pub-id-type="pmid">29651456</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betancur</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting</article-title>
<source/>Brain Res
          <year>2011</year>
<volume>1380</volume>
<fpage>42</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.11.078</pub-id>
<pub-id pub-id-type="pmid">21129364</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Risk factors for autism: translating genomic discoveries into diagnostics</article-title>
<source/>Hum Genet
          <year>2011</year>
<volume>130</volume>
<fpage>123</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-011-1037-2</pub-id>
<pub-id pub-id-type="pmid">21701786</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bishop</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Maybery</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hallmayer</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Using self-report to identify the broad phenotype in parents of children with autistic spectrum disorders: a study using the Autism-Spectrum Quotient</article-title>
<source/>J Child Psychol Psychiatry
          <year>2004</year>
<volume>45</volume>
<fpage>1431</fpage>
<lpage>1436</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-7610.2004.00849.x</pub-id>
<pub-id pub-id-type="pmid">15482503</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goines</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment</article-title>
<source/>Neurotoxicol Teratol
          <year>2013</year>
<volume>36</volume>
<fpage>67</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.ntt.2012.07.006</pub-id>
<pub-id pub-id-type="pmid">22918031</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacFabe</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders</article-title>
<source/>Microb Ecol Health Dis.
          <year>2015</year>
<volume>26</volume>
<fpage>28177</fpage>
<pub-id pub-id-type="doi">10.3402/mehd.v26.28177</pub-id>
<pub-id pub-id-type="pmid">26031685</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandy</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Annual research review: the role of the environment in the developmental psychopathology of autism spectrum condition</article-title>
<source/>J Child Psychol Psychiatry
          <year>2016</year>
<volume>57</volume>
<fpage>271</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1111/jcpp.12501</pub-id>
<pub-id pub-id-type="pmid">26782158</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loke</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The role of epigenetic change in Autism Spectrum Disorders</article-title>
<source/>Front Neurol.
          <year>2015</year>
<volume>6</volume>
<fpage>107</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2015.00107</pub-id>
<pub-id pub-id-type="pmid">26074864</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Suckling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition</article-title>
<source/>Mol Autism.
          <year>2016</year>
<volume>7</volume>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-016-0068-x</pub-id>
<pub-id pub-id-type="pmid">26793298</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Réus</surname>
<given-names>GZ</given-names>
</name>
<name>
<surname>Fries</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Stertz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Badawy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passos</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Barichello</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders</article-title>
<source/>Neuroscience
          <year>2015</year>
<volume>300</volume>
<fpage>141</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.05.018</pub-id>
<pub-id pub-id-type="pmid">25981208</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Achim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Semendeferi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Buckwalter</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism</article-title>
<source/>Biol Psychiatry
          <year>2010</year>
<volume>68</volume>
<fpage>368</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2010</pub-id>
<pub-id pub-id-type="pmid">20674603</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tetreault</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Hakeem</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Allman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wold</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Allman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Microglia in the cerebral cortex in autism</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<fpage>2569</fpage>
<lpage>2584</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-012-1513-0</pub-id>
<pub-id pub-id-type="pmid">22466688</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kern</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Geier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sykes</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Geier</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Relevance of neuroinflammation and encephalitis in autism</article-title>
<source/>Front Cell Neurosci.
          <year>2016</year>
<volume>9</volume>
<fpage>519</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2015.00519</pub-id>
<pub-id pub-id-type="pmid">26834565</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nascimbene</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>
<source/>Ann Neurol
          <year>2005</year>
<volume>57</volume>
<fpage>67</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20315</pub-id>
<pub-id pub-id-type="pmid">15546155</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Powis</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Suckling</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Regional susceptibility to TNF-α induction of murine brain inflammation via classical IKK/NF-κB signalling</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<issue>e39049</issue>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0039049</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sugihara</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ouchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Futatsubashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takebayashi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglial activation in young adults with autism spectrum disorder</article-title>
<source/>JAMA Psychiatry.
          <year>2013</year>
<volume>70</volume>
<fpage>49</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.272</pub-id>
<pub-id pub-id-type="pmid">23404112</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chauhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Oxidative stress in autism</article-title>
<source/>Pathophysiology.
          <year>2006</year>
<volume>13</volume>
<fpage>171</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.pathophys.2006.05.007</pub-id>
<pub-id pub-id-type="pmid">16766163</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Delatorre</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Redox metabolism abnormalities in autistic children associated with mitochondrial disease</article-title>
<source/>Transl Psychiatry.
          <year>2013</year>
<volume>3</volume>
<fpage>e273</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2013.51</pub-id>
<pub-id pub-id-type="pmid">23778583</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghezzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Visconti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Abruzzo</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Bolotta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferreri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features</article-title>
<source/>PLoS ONE.
          <year>2013</year>
<volume>8</volume>
<fpage>e66418</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0066418</pub-id>
<pub-id pub-id-type="pmid">23840462</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Evidence of reactive oxygen species-mediated damage to mitochondrial DNA in children with typical autism</article-title>
<source/>Mol Autism.
          <year>2013</year>
<volume>4</volume>
<fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-2</pub-id>
<pub-id pub-id-type="pmid">23347615</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonhajzerova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ondrejka</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mestanik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mikolka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hrtanek</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mestanikova</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammatory activity in Autism Spectrum Disorder</article-title>
<source/>Adv Exp Med Biol
          <year>2015</year>
<volume>861</volume>
<fpage>93</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1007/5584_2015_145</pub-id>
<pub-id pub-id-type="pmid">26022900</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saresella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Piancone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Marventano</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Zoppis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hernis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zanette</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiple inflammasome complexes are activated in autistic spectrum disorders</article-title>
<source/>Brain Behav Immun
          <year>2016</year>
<volume>57</volume>
<fpage>125</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2016.03.009</pub-id>
<pub-id pub-id-type="pmid">26979869</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anwar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abruzzo</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Pasha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rajpoot</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bolotta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism—a source of biomarkers for clinical diagnosis</article-title>
<source/>Mol Autism.
          <year>2018</year>
<volume>9</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-017-0183-3</pub-id>
<pub-id pub-id-type="pmid">29479405</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolotta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Visconti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fedrizzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Manunta</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Na+, K+-ATPase activity in children with autism spectrum disorder: searching for the reason(s) of its decrease in blood cells</article-title>
<source/>Autism Autism Res.
          <year>2018</year>
<volume>11</volume>
<fpage>1388</fpage>
<pub-id pub-id-type="doi">10.1002/aur.2002</pub-id>
<pub-id pub-id-type="pmid">30120881</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Turrini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bertoldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Campanella</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Spano</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxiredoxin-2 expression is increased in beta-thalassemic mouse red cells but is displaced from the membrane as a marker of oxidative stress</article-title>
<source/>Free Radic Biol Med.
          <year>2010</year>
<volume>49</volume>
<fpage>457</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.05.003</pub-id>
<pub-id pub-id-type="pmid">20488244</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bertoldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mohandas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>An</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bugatti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brunati</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3</article-title>
<source/>Free Radic Biol Med.
          <year>2013</year>
<volume>55</volume>
<fpage>27</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.10.543</pub-id>
<pub-id pub-id-type="pmid">23123411</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pantaleo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferru</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Turrini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bertoldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lupo</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The novel role of peroxiredoxin-2 in red cell membrane protein homeostasis and senescence</article-title>
<source/>Free Radic Biol Med.
          <year>2014</year>
<volume>76</volume>
<fpage>80</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.08.004</pub-id>
<pub-id pub-id-type="pmid">25151118</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Falco</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Iolascon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mohandas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>An</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Siciliano</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The interplay between peroxiredoxin-2 and nuclear factor-erythroid 2 is important in limiting oxidative mediated dysfunction in beta-thalassemic erythropoiesis</article-title>
<source/>Antioxid Redox Signal
          <year>2015</year>
<volume>23</volume>
<fpage>1284</fpage>
<lpage>1297</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2014.6237</pub-id>
<pub-id pub-id-type="pmid">26058667</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Falco</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Federti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iolascon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Levi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxiredoxin-2: a novel regulator of iron homeostasis in ineffective erythropoiesis</article-title>
<source/>Antioxid Redox Signal
          <year>2018</year>
<volume>28</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2017.7051</pub-id>
<pub-id pub-id-type="pmid">28793778</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biondani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turrini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Filippini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Siciliano</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heat-shock protein-27, -70 and peroxiredoxin-II show molecular chaperone function in sickle red cells: evidence from transgenic sickle cell mouse model</article-title>
<source/>Proteomics Clin Appl.
          <year>2008</year>
<volume>2</volume>
<fpage>706</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1002/prca.200780058</pub-id>
<pub-id pub-id-type="pmid">21136868</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Federti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghigo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Andolfo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Siciliano</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension</article-title>
<source/>Free Radic Biol Med.
          <year>2017</year>
<volume>112</volume>
<fpage>376</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017</pub-id>
<pub-id pub-id-type="pmid">28801243</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mullen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hanschmann</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Lillig</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Herzenberg</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Ghezzi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>cysteine oxidation targets peroxiredoxins 1 and 2 for exosomal release through a novel mechanism of redox-dependent secretion</article-title>
<source/>Mol Med
          <year>2015</year>
<volume>21</volume>
<fpage>98</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2015.00033</pub-id>
<pub-id pub-id-type="pmid">25715249</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riddell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Minderman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gollnick</surname>
<given-names>SO</given-names>
</name>
</person-group>
<article-title>Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4</article-title>
<source/>J Immunol.
          <year>2010</year>
<volume>184</volume>
<issue>2</issue>
<fpage>1022</fpage>
<lpage>1030</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0901945</pub-id>
<pub-id pub-id-type="pmid">20018613</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shichita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sakaguchi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain</article-title>
<source/>Nat Med
          <year>2012</year>
<volume>18</volume>
<fpage>911</fpage>
<lpage>917</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2749</pub-id>
<pub-id pub-id-type="pmid">22610280</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schröder</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cardiac peroxiredoxins undergo complex modifications during cardiac oxidant stress</article-title>
<source/>Am J Physiol Heart Circ Physiol.
          <year>2008</year>
<volume>295</volume>
<issue>1</issue>
<fpage>H425</fpage>
<lpage>H433</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00017.2008</pub-id>
<pub-id pub-id-type="pmid">18502910</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Haider</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frischer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury</article-title>
<source/>Brain
          <year>2012</year>
<volume>135</volume>
<fpage>886</fpage>
<lpage>899</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aws012</pub-id>
<pub-id pub-id-type="pmid">22366799</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Seong</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Peroxiredoxin 5 regulates adipogenesis-attenuating oxidative stress in obese mouse models induced by a high-fat diet</article-title>
<source/>Free Radic Biol Med.
          <year>2018</year>
<volume>123</volume>
<fpage>27</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.05.061</pub-id>
<pub-id pub-id-type="pmid">29777756</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Peroxiredoxin 5 prevents amyloid-beta oligomer-induced neuronal cell death by inhibiting ERK-Drp1-mediated mitochondrial fragmentation</article-title>
<source/>Free Radic Biol Med.
          <year>2016</year>
<volume>90</volume>
<fpage>184</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.11.015</pub-id>
<pub-id pub-id-type="pmid">26582373</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XS</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>GJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxiredoxin 2 activates microglia by interacting with Toll-like receptor 4 after subarachnoid hemorrhage</article-title>
<source/>J Neuroinflamm
          <year>2018</year>
<volume>15</volume>
<fpage>87</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-018-1118-4</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease</article-title>
<source/>J Biol Chem
          <year>2008</year>
<volume>283</volume>
<fpage>9986</fpage>
<lpage>9998</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M800426200</pub-id>
<pub-id pub-id-type="pmid">18250162</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuccoli</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Saia-Cereda</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Martins-de-Souza</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The energy metabolism dysfunction in psychiatric disorders postmortem brains: focus on proteomic evidence</article-title>
<source/>Front Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>493</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2017.00493</pub-id>
<pub-id pub-id-type="pmid">28936160</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krapfenbauer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engidawork</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fountoulakis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lubec</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders</article-title>
<source/>Brain Res
          <year>2003</year>
<volume>967</volume>
<fpage>152</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(02)04243-9</pub-id>
<pub-id pub-id-type="pmid">12650976</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abruzzo</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bolotta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Malisardi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Manfredini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frataxin mRNA isoforms in FRDA patients and normal subjects: effect of tocotrienol supplementation</article-title>
<source/>Biomed Res Int
          <year>2013</year>
<volume>2013</volume>
<fpage>276808</fpage>
<pub-id pub-id-type="doi">10.1155/2013/276808</pub-id>
<pub-id pub-id-type="pmid">24175286</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brugnara</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de Franceschi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes</article-title>
<source/>J Cell Physiol
          <year>1993</year>
<volume>154</volume>
<fpage>271</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.1041540209</pub-id>
<pub-id pub-id-type="pmid">8381125</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beneduce</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Falco</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mbiandjeu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chiabrando</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tolosano</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis</article-title>
<source/>Am J Hematol
          <year>2018</year>
<pub-id pub-id-type="doi">10.1002/ajh.25295</pub-id>
<pub-id pub-id-type="pmid">30252956</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Franceschi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tomelleri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brunati</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bovee-Geurts</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Bertoldi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity</article-title>
<source/>Blood
          <year>2011</year>
<volume>118</volume>
<fpage>5652</fpage>
<lpage>5663</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2011-05-355339</pub-id>
<pub-id pub-id-type="pmid">21951684</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lupo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tibaldi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Matté</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Brunati</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Alper</surname>
<given-names>SL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis</article-title>
<source/>Blood
          <year>2016</year>
<volume>128</volume>
<fpage>2976</fpage>
<lpage>2987</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2016-07-727321</pub-id>
<pub-id pub-id-type="pmid">27742708</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Neill</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Circadian clocks in human red blood cells</article-title>
<source/>Nature
          <year>2011</year>
<volume>469</volume>
<fpage>498-03</fpage>
<pub-id pub-id-type="doi">10.1038/nature09702</pub-id>
<pub-id pub-id-type="pmid">21270888</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinna</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pasella</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deiana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baralla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mannu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Masala</surname>
<given-names>AGE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomic analysis of human plasma and peripheral blood mononuclear cells in systemic lupus erythematosus patients</article-title>
<source/>J Immunol Methods
          <year>2017</year>
<volume>446</volume>
<fpage>37</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.jim.2017.03.019</pub-id>
<pub-id pub-id-type="pmid">28390925</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferru</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pantaleo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mannu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Khadjavi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase</article-title>
<source/>Haematologica
          <year>2014</year>
<volume>99</volume>
<fpage>570</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2013.084533</pub-id>
<pub-id pub-id-type="pmid">24038029</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<mixed-citation publication-type="other">World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. World Health Organization, Geneva, p. 263. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/classifications/icd/en/GRNBOOK.pdf">https://www.who.int/classifications/icd/en/GRNBOOK.pdf</ext-link>.</mixed-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hattori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Murayama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Noshita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oikawa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo</article-title>
<source/>J Neurochem
          <year>2003</year>
<volume>86</volume>
<fpage>860</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01918.x</pub-id>
<pub-id pub-id-type="pmid">12887684</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaisant</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Clippe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vander Stricht</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Knoops</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gressens</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Recombinant peroxiredoxin 5 protects against excitotoxic brain lesions in newborn mice</article-title>
<source/>Free Radic Biol Med.
          <year>2003</year>
<volume>34</volume>
<fpage>862</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-5849(02)01440-5</pub-id>
<pub-id pub-id-type="pmid">12654475</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis</article-title>
<source/>Biochem Biophys Res Commun
          <year>2000</year>
<volume>268</volume>
<fpage>921</fpage>
<lpage>927</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.2000.2231</pub-id>
<pub-id pub-id-type="pmid">10679306</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Simoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Linard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hermans</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Knoops</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Goemaere</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Mitochondrial peroxiredoxin-5 as potential modulator of mitochondria-ER crosstalk in MPP+-induced cell death</article-title>
<source/>J Neurochem
          <year>2013</year>
<volume>125</volume>
<fpage>473</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12117</pub-id>
<pub-id pub-id-type="pmid">23216451</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chauhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Essa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wegiel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism</article-title>
<source/>J Neurochem
          <year>2011</year>
<volume>117</volume>
<issue>2</issue>
<fpage>209</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07189.x</pub-id>
<pub-id pub-id-type="pmid">21250997</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pavliv</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nick</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain</article-title>
<source/>Transl Psychiatry.
          <year>2012</year>
<volume>10</volume>
<issue>2</issue>
<fpage>e134</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2012.61</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders</article-title>
<source/>J Neuroinflamm
          <year>2014</year>
<volume>11</volume>
<fpage>189</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-014-0189-0</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Neuro-inflammation, blood-brain barrier, seizures and autism</article-title>
<source/>J Neuroinflamm
          <year>2011</year>
<volume>8</volume>
<fpage>168</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-168</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsuzaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kameno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shimmura</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<fpage>e20470</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0020470</pub-id>
<pub-id pub-id-type="pmid">21647375</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napolioni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ober-Reynolds</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Szelinger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corneveaux</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Pawlowski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ober-Reynolds</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Huentelman</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder</article-title>
<source/>J Neuroinflamm
          <year>2013</year>
<volume>10</volume>
<fpage>38</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-38</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Alterations in plasma cytokine levels in chinese children with autism spectrum disorder</article-title>
<source/>Autism Res.
          <year>2018</year>
<volume>11</volume>
<issue>7</issue>
<fpage>989</fpage>
<lpage>999</lpage>
<pub-id pub-id-type="doi">10.1002/aur.1940</pub-id>
<pub-id pub-id-type="pmid">29522267</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qasem</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bjørklund</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chirumbolo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Impaired lipid metabolism markers to assess the risk of neuroinflammation in autism spectrum disorder</article-title>
<source/>Metab Brain Dis
          <year>2018</year>
<volume>33</volume>
<issue>4</issue>
<fpage>1141</fpage>
<lpage>1153</lpage>
<pub-id pub-id-type="doi">10.1007/s11011-018-0206-6</pub-id>
<pub-id pub-id-type="pmid">29569150</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dobkin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation</article-title>
<source/>J Neuroinflamm
          <year>2011</year>
<volume>8</volume>
<fpage>52</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-52</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname>
<given-names>PH</given-names>
</name>
</person-group>
<article-title>Immune involvement in schizophrenia and autism: etiology, pathology and animal models</article-title>
<source/>Behav Brain Res
          <year>2008</year>
<volume>204</volume>
<fpage>313</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2008.12.016</pub-id>
<pub-id pub-id-type="pmid">19136031</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Borthwick</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Altares</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gauldie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons</article-title>
<source/>Eur J Neurosci
          <year>2000</year>
<volume>12</volume>
<fpage>1891</fpage>
<lpage>1899</lpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.2000.00074.x</pub-id>
<pub-id pub-id-type="pmid">10886330</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Martinowich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Becker-Catania</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis</article-title>
<source/>Nat Neurosci
          <year>2005</year>
<volume>8</volume>
<fpage>616</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1038/nn1440</pub-id>
<pub-id pub-id-type="pmid">15852015</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domingues</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Nasuti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Piangerelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Correia-Sá</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pyrethroid pesticide metabolite in urine and microelements in hair of children affected by Autism Spectrum Disorders: a preliminary investigation</article-title>
<source/>Int J Environ Res Public Health.
          <year>2016</year>
<volume>13</volume>
<fpage>388</fpage>
<pub-id pub-id-type="doi">10.3390/ijerph13040388</pub-id>
<pub-id pub-id-type="pmid">27482573</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Essa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>de Paula</surname>
<given-names>Martins R</given-names>
</name>
<name>
<surname>Lovejoy</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Bilgin</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Waly</surname>
<given-names>MI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered kynurenine pathway metabolism in autism: implication for immune-induced glutamatergic activity</article-title>
<source/>Autism Res.
          <year>2016</year>
<volume>6</volume>
<fpage>621</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="doi">10.1002/aur.1565</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gevi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zolla</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gabriele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism</article-title>
<source/>Mol Autism.
          <year>2016</year>
<volume>7</volume>
<fpage>47</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-016-0109-5</pub-id>
<pub-id pub-id-type="pmid">27904735</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollingshead</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Beischlag</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Dinatale</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Ramadoss</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Perdew</surname>
<given-names>GH</given-names>
</name>
</person-group>
<article-title>Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells</article-title>
<source/>Cancer Res
          <year>2008</year>
<volume>68</volume>
<fpage>3609</fpage>
<lpage>3617</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472</pub-id>
<pub-id pub-id-type="pmid">18483242</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hahn</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Allan</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Sherr</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor</article-title>
<source/>Biochem Pharmacol
          <year>2009</year>
<volume>77</volume>
<fpage>485</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2008.09.016</pub-id>
<pub-id pub-id-type="pmid">18848529</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiNatale</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Flaveny</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Lahoti</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Laurenzana</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling</article-title>
<source/>Toxicol Sci
          <year>2010</year>
<volume>115</volume>
<fpage>89</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1093/toxsci/kfq024</pub-id>
<pub-id pub-id-type="pmid">20106948</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>John</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Krock</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Randall</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Karp</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The aryl hydrocarbon receptor promotes IL-10 production by NK cells</article-title>
<source/>J Immunol.
          <year>2014</year>
<volume>192</volume>
<fpage>1661</fpage>
<lpage>1670</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1300497</pub-id>
<pub-id pub-id-type="pmid">24403534</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stobbe-Maicherski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Abel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sydlik</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Frauenstein</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The interleukin-6-type cytokine oncostatin M induces aryl hydrocarbon receptor expression in a STAT3-dependent manner in human HepG2 hepatoma cells</article-title>
<source/>FEBS J
          <year>2013</year>
<volume>280</volume>
<fpage>6681</fpage>
<lpage>6690</lpage>
<pub-id pub-id-type="doi">10.1111/febs.12571</pub-id>
<pub-id pub-id-type="pmid">24127753</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>An</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Leak</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection</article-title>
<source/>Prog Neurobiol
          <year>2013</year>
<volume>100</volume>
<fpage>30</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2012.09.003</pub-id>
<pub-id pub-id-type="pmid">23025925</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiering</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wincent</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Metidji</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iseppon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Potocnik</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Feedback control of AHR signalling regulates intestinal immunity</article-title>
<source/>Nature
          <year>2017</year>
<volume>542</volume>
<fpage>242</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1038/nature21080</pub-id>
<pub-id pub-id-type="pmid">28146477</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Emerging trends and research foci in gastrointestinal microbiome</article-title>
<source/>J Transl Med.
          <year>2019</year>
<volume>17</volume>
<issue>1</issue>
<fpage>67</fpage>
<pub-id pub-id-type="doi">10.1186/s12967-019-1810-x</pub-id>
<pub-id pub-id-type="pmid">30819194</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Padua</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tillisch</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Altered brain-gut axis in autism: comorbidity or causative mechanisms?</article-title>
<source/>BioEssays
          <year>2014</year>
<volume>36</volume>
<fpage>933</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1002/bies.201400075</pub-id>
<pub-id pub-id-type="pmid">25145752</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Serena</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sturgeon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential immune responses and microbiota profiles in children with autism spectrum disorders and co-morbid gastrointestinal symptoms</article-title>
<source/>Brain Behav Immun
          <year>2018</year>
<volume>70</volume>
<fpage>354</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2018.03.025</pub-id>
<pub-id pub-id-type="pmid">29571898</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anwar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abruzzo</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Bolotta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Visconti</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantitation of plasma thiamine, related metabolites and plasma protein oxidative damage markers in children with autism spectrum disorder and healthy controls</article-title>
<source/>Free Radic Res.
          <year>2016</year>
<volume>50</volume>
<issue>suppl1</issue>
<fpage>S85</fpage>
<lpage>S90</lpage>
<pub-id pub-id-type="doi">10.1080/10715762.2016.1239821</pub-id>
<pub-id pub-id-type="pmid">27667096</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Shong</surname>
<given-names>MH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of neural cell types expressing peroxiredoxins in mouse brain</article-title>
<source/>Neurosci Lett
          <year>2005</year>
<volume>381</volume>
<fpage>252</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2005.02.048</pub-id>
<pub-id pub-id-type="pmid">15896479</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunze</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zierath</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tanzi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cain</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Peroxiredoxin 5 (PRX5) is correlated inversely to systemic markers of inflammation in acute stroke</article-title>
<source/>Stroke
          <year>2014</year>
<volume>45</volume>
<issue>2</issue>
<fpage>608</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.113.003813</pub-id>
<pub-id pub-id-type="pmid">24385276</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Yafee</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Haq</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>El-Ansary</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia</article-title>
<source/>BMC Neurol.
          <year>2011</year>
<volume>11</volume>
<fpage>139</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2377-11-139</pub-id>
<pub-id pub-id-type="pmid">22051046</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>